ADYX (Adynxx) FCF Margin %: 0.00% (As of Sep. 2019)


ADYX Adynxx Inc ADYX
16 GF Score
Price $0.00
View Full Analysis

What is Adynxx FCF Margin %?

Adynxx ADYX -99.00% 16 FCF Margin % is 0.00% as of Sep. 2019. GuruFocus rates ADYX with a GF Score™ of 16/100.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Adynxx's Free Cash Flow for the three months ended in Sep. 2019 was $-0.54 Mil. Adynxx's Revenue for the three months ended in Sep. 2019 was $0.00 Mil. Therefore, Adynxx's FCF Margin % for the quarter that ended in Sep. 2019 was 0.00%.

As of today, Adynxx's current FCF Yield % is 0.00%.

The historical rank and industry rank for Adynxx's FCF Margin % or its related term are showing as below:

ADYX' s FCF Margin % Range Over the Past 10 Years
Min: -1170.29   Med: 0   Max: 0
Current: -1170.29

ADYX's FCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -85.21 vs ADYX: -1170.29

Adynxx FCF Margin % Related Terms

Adynxx FCF Margin % Historical Data

* Premium members only.

The historical data trend for Adynxx's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adynxx FCF Margin % Chart

Adynxx Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -284.81 -181.04 -118.01 -537.44 -438.18

Adynxx Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -36.21 -462.17 -890.70 0.00 0.00

ADYX vs TRPX, MITI, RASP: FCF Margin % Comparison

For the Biotechnology subindustry, Adynxx's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adynxx FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adynxx's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Adynxx's FCF Margin % falls into.


ADYX
16GF Score
Adynxx Inc ADYX
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adynxx FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Adynxx's FCF Margin for the fiscal year that ended in Dec. 2018 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2018 )/Revenue (A: Dec. 2018 )
=-9.71/2.216
=-438.18 %

Adynxx's FCF Margin for the quarter that ended in Sep. 2019 is calculated as

FCF Margin=Free Cash Flow (Q: Sep. 2019 )/Revenue (Q: Sep. 2019 )
=-0.544/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Adynxx (ADYX) has a FCF Margin % of 0.00% as of Sep. 2019. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Adynxx and its competitors.
Is Adynxx's FCF Margin % too high?
Adynxx's current FCF Margin % is 0.00%. Overall, Adynxx has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Adynxx's FCF Margin % compare to TRPX and MITI?
Adynxx's FCF Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Adynxx and its competitors. Adynxx's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adynxx stock overvalued right now?
Adynxx (ADYX) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Adynxx's overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Adynxx (ADYX), the current FCF Margin % is 0.00% as of Sep. 2019. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adynxx Business Description

Address 100 Pine Street, Suite 500, San Francisco, CA, USA, 94111
Adynxx Inc is a United States-based clinical-stage biopharmaceutical company. It is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to the market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. Its pipeline includes brivoligide, a Phase 2 drug candidate intended to address postoperative pain, and AYX2, a pre-clinical candidate intended to treat chronic syndromes of pain, including both inflammatory and neuropathic pain.
16GF Score

Get the complete analysis for ADYX

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price